Finally, multivariate analysis indicated that high inclusion levels of ECT2-Ex5 were an independent predictive marker of bad prognosis in the subgroup of 120 HR+ERBB2- breast cancer patients treated with chemotherapy (Supplementary Tables S3 and S7). Here, ERBB2 is linked to breast carcinoma.